METHODS OF USING PPAR-gamma AGONISTS AND CASPASE-DEPENDENT CHEMOTHERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER
AssigneeCedars-Sinai Medical Center
InventorJohn S. Yu
Life of this patent
Estimating the term…
Abstract
This invention relates to compositions and methods utilizing a caspase-dependent chemotherapeutic drug and a PPARy-agonist, such as VP-16 or Taxol as the chemotherapeutic drug and troglitazone or pioglitazone as the PPARy agonist, for the treatment of cancer, including glioblastoma multiforme. The present invention demonstrates that PPAR agonists work with caspase-dependent chemotherapeutic drugs to increase the cytotoxic effects of these drugs in glioma cells.
Claims28
A method of treating cancer in a mammal in need thereof comprising:
- providing a caspase-dependent chemotherapeutic agent and a peroxisome proliferator-activated receptor-γ (“PPARγ”) agonist;
- and
- administering a therapeutically effective amount of the caspase-dependent chemotherapeutic agent and a therapeutically effective amount the PPARγ agonist to the mammal in need of treatment for cancer.
A composition for the treatment of cancer in a mammal in need thereof comprising:
- a caspase-dependent chemotherapeutic agent;
- and
- a peroxisome proliferator-activated receptor-γ (“PPARγ”) agonist.
A kit for the treatment of cancer in a mammal in need thereof, comprising:
- a quantity of a caspase-dependent chemotherapeutic agent;
- a quantity of a peroxisome proliferator-activated receptor-γ (“PPARγ”) agonist;
- and
- instructions to administer a therapeutically effective amount of the caspase-dependent chemotherapeutic agent and a therapeutically effective amount the PPARγ agonist to the mammal in need of treatment for cancer.
Dependencies are inferred from the claim text.